{
    "clinical_study": {
        "@rank": "90748", 
        "arm_group": {
            "arm_group_label": "Recombinant HSV-1 Injection", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds\n      of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer."
        }, 
        "brief_title": "A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Melanoma", 
            "Liver Cancer", 
            "Pancreatic Cancer", 
            "Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Herpes Simplex", 
                "Liver Neoplasms", 
                "Lung Neoplasms", 
                "Melanoma", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients in advanced stage of malignant tumor diagnosticated by pathologic  and\n             cytological analysis.\n\n          -  lack of routine effective treatment,failure of routine treatment or relapse\n\n          -  age of 18-70,ECOG 0-2 and estimated survival is above 3 months\n\n          -  had an interval of above 4 weeks since exposure to chemotherapy or radiotherapy and\n             above 6 weeks since exposure to nitrosoureas or mitomycin C.\n\n        Exclusion Criteria:\n\n          -  Serious internal diseases\n\n          -  uncontrolled primary and metastatic brain tumor\n\n          -  sizes of tumor does not meet the requirement of injection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935453", 
            "org_study_id": "OrienGene-01"
        }, 
        "intervention": {
            "arm_group_label": "Recombinant HSV-1 Injection", 
            "intervention_name": "Recombinant hGM-CSF Herpes Simplex Virus Injection", 
            "intervention_type": "Biological", 
            "other_name": "OrienX010"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 30, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Xinna Zhou", 
                    "phone": "86-10-63926220"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100038"
                    }, 
                    "name": "Beijing Shijitan Hospital,CMU"
                }, 
                "investigator": {
                    "last_name": "Jun Ren, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fudanlijin@163.com", 
                    "last_name": "Jin Li, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200032"
                    }, 
                    "name": "Fudan University Shanghai Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Jin Li, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus", 
        "overall_official": [
            {
                "affiliation": "Fudan University", 
                "last_name": "Jin Li, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Beijing Shijitan Hospital,CMU", 
                "last_name": "Jun Ren, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Exploring the MTD of OrienX010 according to DLT,which defined as the serious degree of adverse events relates to the medicine not less than grade 3 of CTCAE v4.03", 
            "safety_issue": "Yes", 
            "time_frame": "28 days after the last administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935453"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Using RECIST 1.1 to evaluate the preliminary efficacy of OrienX010", 
            "safety_issue": "Yes", 
            "time_frame": "28 days after the last administration"
        }, 
        "source": "OrienGene Biotechnology Ltd.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "START Shanghai Company Limited", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Beijing Bozhiyin T&S Co., Ltd.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "OrienGene Biotechnology Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}